In addition, in silico clinical analyses of tumor databases have indicated that a two-fold upregulation of A20 significantly correlated with decreased survival in patients with grade II or III, but not IV, astrocytomas [73,74]. This evidence concerns the gene TNFAIP3 and neoplasm.